Literature DB >> 30291560

Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure.

Ryousuke Satou1, Harrison Penrose2, L Gabriel Navar2.   

Abstract

PURPOSE OF REVIEW: Mechanisms facilitating progression of hypertension via cross stimulation of the renin-angiotensin system (RAS) and inflammation have been proposed. Accordingly, we review and update evidence for regulation of RAS components by pro-inflammatory factors. RECENT
FINDINGS: Angiotensin II (Ang II), which is produced by RAS, induces vasoconstriction and consequent blood pressure elevation. In addition to this direct action, chronically elevated Ang II stimulates several pathophysiological mechanisms including generation of oxidative stress, stimulation of the nervous system, alterations in renal hemodynamics, and activation of the immune system. In particular, an activated immune system has been shown to contribute to the development of hypertension. Recent studies have demonstrated that immune cell-derived pro-inflammatory cytokines regulate RAS components, further accelerating systemic and local Ang II formation. Specifically, regulation of angiotensinogen (AGT) production by pro-inflammatory cytokines in the liver and kidney is proposed as a key mechanism underlying the progression of Ang II-dependent hypertension.

Entities:  

Keywords:  Hypertension; Inflammation; Intracellular signaling; The renin-angiotensin system

Mesh:

Substances:

Year:  2018        PMID: 30291560      PMCID: PMC6203444          DOI: 10.1007/s11906-018-0900-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  94 in total

Review 1.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

2.  Angiotensin II hypertension is attenuated in interleukin-6 knockout mice.

Authors:  Dexter L Lee; Lashon C Sturgis; Hicham Labazi; James B Osborne; Cassandra Fleming; Jennifer S Pollock; Marlina Manhiani; John D Imig; Michael W Brands
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-11       Impact factor: 4.733

3.  Interleukin-1beta attenuates renin gene expression via a mitogen-activated protein kinase kinase-extracellular signal-regulated kinase and signal transducer and activator of transcription 3-dependent mechanism in As4.1 cells.

Authors:  Xuebo Liu; Qi Shi; Curt D Sigmund
Journal:  Endocrinology       Date:  2006-09-07       Impact factor: 4.736

Review 4.  The role of macrophages in hypertension and its complications.

Authors:  A Justin Rucker; Steven D Crowley
Journal:  Pflugers Arch       Date:  2017-03-01       Impact factor: 3.657

5.  Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats.

Authors:  Lian Hu; Da-Nian Zhu; Zhang Yu; John Q Wang; Zhong-Jie Sun; Tai Yao
Journal:  J Appl Physiol (1985)       Date:  2002-05

6.  Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis.

Authors:  Jian-dong Zhang; Mehul B Patel; Robert Griffiths; Paul C Dolber; Phillip Ruiz; Matthew A Sparks; Johannes Stegbauer; Huixia Jin; Jose A Gomez; Anne F Buckley; William S Lefler; Daian Chen; Steven D Crowley
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

7.  Enhancer-dependent inhibition of mouse renin transcription by inflammatory cytokines.

Authors:  Li Pan; Yanping Wang; Craig A Jones; Sean T Glenn; Heinz Baumann; Kenneth W Gross
Journal:  Am J Physiol Renal Physiol       Date:  2004-09-14

8.  Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy.

Authors:  Srinivas Sriramula; Masudul Haque; Dewan S A Majid; Joseph Francis
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats.

Authors:  A A Khraibi; R A Norman; D J Dzielak
Journal:  Am J Physiol       Date:  1984-11

10.  Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.

Authors:  Barbara Coles; Ceri A Fielding; Stefan Rose-John; Jürgen Scheller; Simon A Jones; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more
  33 in total

1.  Augmenting Renal Lymphatic Density Prevents Angiotensin II-Induced Hypertension in Male and Female Mice.

Authors:  Dakshnapriya Balasubbramanian; Catalina A Lopez Gelston; Alexandra H Lopez; Geina Iskander; Winter Tate; Haley Holderness; Joseph M Rutkowski; Brett M Mitchell
Journal:  Am J Hypertens       Date:  2020-01-01       Impact factor: 2.689

2.  Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19.

Authors:  Mauro G Silva; Gerardo R Corradi; Juan I Pérez Duhalde; Myriam Nuñez; Eliana M Cela; Daniel H Gonzales Maglio; Ana Brizzio; Martin R Salazar; Walter G Espeche; Mariela M Gironacci
Journal:  Biomed Pharmacother       Date:  2022-05-27       Impact factor: 7.419

3.  Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.

Authors:  Iuliia Polina; Mark Domondon; Rebecca Fox; Anastasia V Sudarikova; Miguel Troncoso; Valeriia Y Vasileva; Yuliia Kashyrina; Monika Beck Gooz; Ryan S Schibalski; Kristine Y DeLeon-Pennell; Wayne R Fitzgibbon; Daria V Ilatovskaya
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-28

Review 4.  The evolving complexity of the collecting duct renin-angiotensin system in hypertension.

Authors:  Minolfa C Prieto; Alexis A Gonzalez; Bruna Visniauskas; L Gabriel Navar
Journal:  Nat Rev Nephrol       Date:  2021-04-06       Impact factor: 28.314

Review 5.  Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.

Authors:  Abdelrahman AlAshqar; Lauren Reschke; Gregory W Kirschen; Mostafa A Borahay
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

6.  Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19).

Authors:  Armin Krvavac; Tarang P Patel; Ethan M Karle; Nicholas B Epstein; Elizabeth A Reznikov; Lancer G Gates; Zachary M Holliday
Journal:  Mo Med       Date:  2020 Jul-Aug

7.  Anti-Inflammatory Effect of Auranofin on Palmitic Acid and LPS-Induced Inflammatory Response by Modulating TLR4 and NOX4-Mediated NF-κB Signaling Pathway in RAW264.7 Macrophages.

Authors:  Hyun Hwangbo; Seon Yeong Ji; Min Yeong Kim; So Young Kim; Hyesook Lee; Gi-Young Kim; Suhkmann Kim; JaeHun Cheong; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

8.  Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19.

Authors:  Azadeh Khalili; Hosein Karim; Gholamreza Bayat
Journal:  Iran J Med Sci       Date:  2021-07

Review 9.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

Review 10.  The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity.

Authors:  Ioannis Akoumianakis; Theodosios Filippatos
Journal:  Obes Rev       Date:  2020-06-22       Impact factor: 10.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.